Faculty profile

Marie-Claude Bourgeois-Daigneault

ResearcherCancer ResearchUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Marie-Claude Bourgeois-Daigneault

Researcher

Cancer Research

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
11 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (5 CIHR, 1 SSHRC), most recently in 2025.
Supervised 1 trainee who won CIHR awards, most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Oncolytic Virus Vesicular Stomatitis Virus Molecular Tnbc Subtypes Therapy Triple-Negative Breast Cancer Cancer Therapy Estrogen

Latest papers

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026 · senior author
The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.
Vaccines · 2025 · senior author
From oncogenesis to prognosis: the roles of the immunoproteasome in cancer.
Frontiers in immunology · 2025 · senior author

All 21 publications

Latest funding

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy
CIHR · 2025 · Nominated PI
$1,120,725
Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy
CIHR · 2025 · Nominated PI
$25,000
Étude de l'environnement immunologique prédisant une réponse antitumorale à long terme suite au traitement du cancer par les virus oncolytiques
CIHR · 2022 · Supervisor
$105,000

All 7 grants and awards

21 publications.

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Viens M, Geoffroy K, Meuriot E, Buccilli A, Mullins-Dansereau V, Myre ML, Paradisis S, Bardoul A, Kalin EM, Saraiva BA, Valencia J, Leclerc Desaulniers K, Hoang HD, Hassan S, Bell JC, Vanderhyden B, Alain T, Roy DG, Cook DP, Bourgeois-Daigneault MC

Molecular therapy : the journal of the American Society of Gene Therapy2026Senior author

DOI: 10.1016/j.ymthe.2026.04.061 PMID: 42093158

The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.

Béland D, Mullins-Dansereau V, Geoffroy K, Viens M, Leclerc Desaulniers K, Bourgeois-Daigneault MC

Vaccines2025Senior author

DOI: 10.3390/vaccines13080835 PMID: 40872920

From oncogenesis to prognosis: the roles of the immunoproteasome in cancer.

Béland D, Viens M, Kalin EM, Bourgeois-Daigneault MC

Frontiers in immunology2025Senior author

DOI: 10.3389/fimmu.2025.1603816 PMID: 40698074

Ultrasound and Microbubble Mediated Delivery of Virus-Sensitizing Drugs Improves In Vitro Oncolytic Virotherapy Against Breast Cancer Cells.

Italiya KS, Mullins-Dansereau V, Geoffroy K, Gilchrist VH, Alain T, Bourgeois-Daigneault MC, Yu F

Ultrasound in medicine & biology2025

DOI: 10.1016/j.ultrasmedbio.2025.03.010 PMID: 40234152

Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.

Mullins-Dansereau V, Myre ML, Bardoul A, Geoffroy K, Rallo Pita MJ, Béland D, Desaulniers KL, Roy DG, Bourgeois-Daigneault MC

Journal for immunotherapy of cancer2025Senior author

DOI: 10.1136/jitc-2024-010570 PMID: 40389376

RNAi Screening in Tumor Cells Identifies Artificial microRNAs That Improve Oncolytic Virus Replication.

Klemets H, Bardoul A, Pelin A, Singaravelu R, Boileau M, Falls T, Petryk J, Bourgeois-Daigneault MC, Bell JC, Roy DG

Pharmaceuticals (Basel, Switzerland)2025

DOI: 10.3390/ph18050708 PMID: 40430527

The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Geoffroy K, Viens M, Kalin EM, Boudhraa Z, Roy DG, Wu JH, Provencher D, Mes-Masson AM, Bourgeois-Daigneault MC

Pharmaceuticals (Basel, Switzerland)2024Senior author

DOI: 10.3390/ph17121662 PMID: 39770503

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.

Geoffroy K, Mullins-Dansereau V, Leclerc-Desaulniers K, Viens M, Bourgeois-Daigneault MC

Molecular therapy. Oncology2024Senior author

DOI: 10.1016/j.omton.2024.200826 PMID: 39006945

PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.

Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, Marotel M, Buchler A, Fadel S, Park MM, Fong-McMaster C, Crupi MF, Makinson OJ, Kurdieh R, Rezaei R, Dhillon HS, Ilkow CS, Bell JC, Harper ME, Rotstein BH, Auer RC, Vanderhyden BC, Sabourin LA, Bourgeois-Daigneault MC, Cook DP, Ardolino M

The Journal of experimental medicine2024

DOI: 10.1084/jem.20221721 PMID: 38869480

Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.

Geoffroy K, Araripe Saraiva B, Viens M, Béland D, Bourgeois-Daigneault MC

Scientific reports2023Senior author

DOI: 10.1038/s41598-023-28940-2 PMID: 36746983

Something wrong or missing on this profile? Suggest a correction

Marie-Claude Bourgeois-Daigneault

Research

Latest papers

Latest funding

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.

From oncogenesis to prognosis: the roles of the immunoproteasome in cancer.

Ultrasound and Microbubble Mediated Delivery of Virus-Sensitizing Drugs Improves In Vitro Oncolytic Virotherapy Against Breast Cancer Cells.

Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.

RNAi Screening in Tumor Cells Identifies Artificial microRNAs That Improve Oncolytic Virus Replication.

The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.

PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.

Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Étude de l'environnement immunologique prédisant une réponse antitumorale à long terme suite au traitement du cancer par les virus oncolytiques

Investigating the role of the immunoproteasome in the efficacy of oncolytic virotherapy against breast cancer

Early Career Award in Cancer: To uncover, understand and exploit the estrogen-oncolytic virus crosstalk to improve therapy

To uncover, understand and exploit the estrogen-oncolytic virus crosstalk to improve therapy

Combining microbubble-mediated drug delivery and oncolytic virotherapy for cancer treatment

Frequent collaborators

Jacques Thibodeau

Tommy Alain

Anne-Marie Mes-Masson

Morgan Craig

Morgan Craig

William Foulkes

Mary-Ellen Harper

Barbara Vanderhyden

John Stagg

Daniel Lamarre

Sylvie Lesage

Michele Ardolino

Dominique Trudel

Karen Mossman

Dominique Trudel

Michael Witcher

CHEOLHO Cheong

Marie-Claude Bourgeois-Daigneault

Research

Latest papers

Latest funding

Estrogen-mediated NF-&#x3ba;B blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.

From oncogenesis to prognosis: the roles of the immunoproteasome in cancer.

Ultrasound and Microbubble Mediated Delivery of Virus-Sensitizing Drugs Improves In Vitro Oncolytic Virotherapy Against Breast Cancer Cells.

Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.

RNAi Screening in Tumor Cells Identifies Artificial microRNAs That Improve Oncolytic Virus Replication.

The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.

PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.

Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Étude de l'environnement immunologique prédisant une réponse antitumorale à long terme suite au traitement du cancer par les virus oncolytiques

Investigating the role of the immunoproteasome in the efficacy of oncolytic virotherapy against breast cancer

Early Career Award in Cancer: To uncover, understand and exploit the estrogen-oncolytic virus crosstalk to improve therapy

To uncover, understand and exploit the estrogen-oncolytic virus crosstalk to improve therapy

Combining microbubble-mediated drug delivery and oncolytic virotherapy for cancer treatment

Frequent collaborators

Jacques Thibodeau

Tommy Alain

Anne-Marie Mes-Masson

Morgan Craig

Morgan Craig

William Foulkes

Mary-Ellen Harper

Barbara Vanderhyden

John Stagg

Daniel Lamarre

Sylvie Lesage

Michele Ardolino

Dominique Trudel

Karen Mossman

Dominique Trudel

Michael Witcher

CHEOLHO Cheong

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.